Home

Bernard Coulie

CIK 1808895 · President and CEO · last filed 2026-04-17

Bernard Coulie is a President and CEO who has filed 36 SEC Form 4 insider transactions across 3 companies since 2020. The most recent filing, for PLRX, was dated Apr 17, 2026. Across all open-market trades the lifetime net is −$13.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.1M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.07M

Companies

3

Total Filings

36

Lifetime Open-Market Net

-$13.58M

Filer Profile

Reported Address
C/O PLIANT THERAPEUTICS, INC.
331 OYSTER POINT BOULEVARD
SOUTH SAN FRANCISCO, CA 94080
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
PLRX President and CEO 914,918 $1.17 $1.07M -$13.58M 32 2026-04-17
SEPN Director — $38.51 — $0 1 2025-06-20
SQZ Biotechnologies Co (SQZ) Delisted Director — $0.43 — $0 3 2023-06-15

Recent Filings

36 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-04-17 PLRX Mixed — $0 EDGAR
2026-01-26 PLRX Grant (A) — $0 EDGAR
2026-01-22 PLRX Sell (S) −89,375 -$114.4K EDGAR
2025-06-20 SEPN Grant (A) — $0 EDGAR
2025-01-27 PLRX Grant (A) +162,500 $0 EDGAR
2025-01-22 PLRX Sell (S) −52,419 -$587.2K EDGAR
2024-07-12 PLRX Sell (S) −38,710 -$447.5K EDGAR
2024-07-11 PLRX Grant (A) +75,625 $0 EDGAR
2024-01-24 PLRX Grant (A) +128,150 $0 EDGAR
2024-01-19 PLRX Sell (S) −25,721 -$443.2K EDGAR
Showing 1–10 of 36
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.